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Abstract Stimulation of neurotensin (NT) type 1 receptors
(NT1-R) in transfected CHO cells is followed by the activation
of mitogen-activated protein kinases and the expression of the
early response gene krox24. By making point mutations and
internal deletions in the krox24 promoter, we show that proximal
serum responsive elements (SRE) are involved in transcriptional
activation by NT. In addition, we show that the related early
response gene c-fos and the Ets protein Elk-1 are also induced by
NT. The involvement of NT1-R in NT-mediated activation of
krox24, c-fos and Elk-1 was demonstrated by the preventing
effect of the specific antagonists SR 48692 and SR 142948.
Finally, we show that the activation of krox24 and Elk-1 on the
one hand, and that of c-fos on the other hand, result from
independent transduction pathways since the former are pertussis
toxin-sensitive whereas the latter is insensitive to pertussis toxin.
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1. Introduction
Neurotensin (NT) is a tridecapeptide which interacts with
speci¢c G protein-coupled receptors belonging to the seven
transmembrane receptor superfamily, and mediates various
biological functions in the central nervous system and periph-
eral organs [1]. The ¢rst originally cloned receptor for NT
(NT1-R) binds NT with high a⁄nity and is insensitive to
the histamine H1 receptor antagonist levocabastine [2]. The
genomic structure of the human NT1-R gene was recently
characterized and reveals the presence of three introns within
the coding sequence, a proximal promoter sequence rich in
putative transcription factor binding sites, and a tetranucleo-
tide repeat polymorphism within the 3P-£anking region, with
at least 23 alleles [3]. Rat NT1-R cDNA leads to the expres-
sion of two proteins with high a⁄nity for NT, generated by
the use of alternative translation initiation sites [4]. A second
type of receptor (NT2-R) was cloned in rats [5], mice [6] and
recently in humans [7], and di¡ers from NT1-R in its low
a⁄nity for NT and its sensitivity to levocabastine. The mouse
NT2-R is only 36% homologous to mouse NT1-R in global
amino acid sequence, with increasing homology (60^75%)
within transmembrane domains and extracellular loops [6].
Messenger RNAs for a deleted variant of NT2-R were iden-
ti¢ed in mouse brain, but were shown to encode a non-func-
tional receptor [8]. We have characterized two potent and
selective non-peptide antagonists for NT1-R, SR 48692 [9]
and SR 142948 [10]. The binding domains of NT and SR
48692 on NT1-R were recently described to be distinct [11].
Unexpectedly, we have recently demonstrated that both SR
48692 and SR 142948 behave as potent agonists on NT2-R
when assayed on inositol phosphate formation, calcium mo-
bilization and arachidonic acid release [7]. In addition, NT
alone does not elicit a biological response on NT2-R but
completely antagonizes the e¡ect of SR 48692 and SR
142948 [7].
Many of the central e¡ects of NT are thought to involve
interactions with dopamine systems [12]. Physiological or
pharmacological neuronal stimulation activates several tran-
scription factors, and following intrathecal administration of
NT in rats, discrete sites of nuclei within the amygdala and
hypothalamus have been shown to be immunoreactive with
speci¢c antibodies for c-fos and krox24 [13]. We have also
described that stimulation by NT of NT1-R-transfected
CHO cells induces a transient activation of p42/p44 mito-
gen-activated protein kinases (MAPKs) and the expression
of the krox24 gene, both of which are thought to be mediated
by the GLQ subunits of the G protein-coupled receptor [14]. In
this study, we investigated in detail the signalling components
from NT1-R leading to induction of krox24 and c-fos genes in
CHO cells.
2. Materials and methods
2.1. Reagents
Neurotensin and forskolin were purchased from Sigma Chemicals
(St Quentin Fallavier, France). The non-peptide NT receptor antag-
onists SR 48692 [8] and SR 144528 [9] were synthesized in the Chem-
istry Department of Sano¢ Recherche (Montpellier, France). Pertussis
toxin (PTX) and GF109203X were purchased from Calbiochem
(Meudon, France).
2.2. Plasmids
The original plasmids containing deletions of the murine krox24
promoter as well as the mutant form of SRE3, located upstream of
chloramphenicol acetyltransferase (CAT), were previously published
[15]: pBL395 contains the sequence 3395 to +65 with respect to the
initiation start site, pBL395v274 is pBL395 deleted for the portion
3274/+45, pBL395v335 is pBL395 deleted for the portion 3335/+45,
and pBL395mSRE3 is derived from pBL395 by PCR-generated point
mutations in the SRE3. Inserts were subcloned as XbaI fragments into
the SpeI site of pUT112 (Eurogentech, Seraing, Belgium), upstream of
the ¢re£y luciferase coding sequence. The expression vector for hu-
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man NT1-R (p1274) as well as the corresponding empty vector (p658)
were previously described [14]. pAdFosLuc was kindly provided by
A.P. Czernilofsky (Vienna, Austria). The trans reporting system for
Elk-1 (Stratagene, La Jolla, CA) consists of a plasmid containing the
activation domains of Elk-1 linked to the DNA binding domain of
Gal4 (Gal4/Elk-1) and a reporter plasmid containing ¢ve Gal4 DNA
binding sites cloned upstream of a minimal promoter and the ¢re£y
luciferase gene (pFR-Luc).
2.3. Transient transfections and luciferase assay
CHO cells were maintained in KMEM medium (Gibco-BRL, Cergy
Pontoise, France) containing ribonucleosides and deoxyribonucleo-
sides, and supplemented with 10% fetal calf serum (FCS) and anti-
biotics. For transfections, exponentially growing cells were electropo-
rated in PBS bu¡er together with a maximal amount of 15 Wg plasmid
as already described [14]. Following transfection, cells were diluted in
complete KMEM medium, plated in 96-well microplates, and incu-
bated overnight at 37‡C. The next day, the medium was removed
and replaced with FCS-free medium. Cells were further incubated
for 24 h at 37‡C before stimulation. For the analysis of krox24-
and c-fos-luciferase genes, cells were stimulated for 90 min with NT.
In the Elk-1 transactivation assay, cells were stimulated for 5 h with
NT. When indicated, cells were treated for 5 min with SR 48692 or
SR 142948 before adding NT. Following stimulation, cells were
washed twice with PBS, cell extracts were prepared using the Cell
Culture Lysis Reagent (Promega, CharbonnieØres, France), and lucifer-
ase activities were determined using the Luciferase Assay System
(Promega) and a CCD camera (MTP Reader, Hamamatsu Photonics,
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Fig. 1. krox24 reporter constructions. A: Schematic illustration of the reporter plasmid containing the Wt murine krox24 promoter, the plasmid
deleted for the 3274/345 or the 3335/345 sequence, and the plasmid containing the mutated version of the SRE3. The open squares represent
the SREs, the open circle the CRE and the closed circles the Ets motifs. B, C: CHO Wt cells were co-transfected with 5 Wg of the expression
vector for hNT1-R (p1274) or the empty vector (p658) and 10 Wg of the krox24 reporter construct, as indicated. Basal luciferase activities in
unstimulated cells were determined as described in Section 2. Mean results from triplicate samples are expressed in relative light units (RLUs).
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Hamamatsu, Japan). Mean luciferase values from triplicate samples
were expressed in relative light units (RLU) or as fold increase, de-
¢ned by the ratios of RLU in stimulated versus unstimulated cells. All
experiments were repeated at least three times.
2.4. Western blot analysis
CHO wild-type cells (CHO Wt) or CHO cells stably expressing
hNT1-R [14] were stimulated for 90 min with NT receptor ligands
before being lysed in Laemmli’s bu¡er containing 6 M urea. When
indicated, cells were treated for 5 min with the antagonists SR 48692
or SR 142948 before the addition of NT. Preparation of proteins and
conditions of Western blot were previously published [14]. Brie£y, cell
extracts were heated for 5 min at 95‡C and proteins were fractionated
by SDS-PAGE on a 4^20% gradient acrylamide gel. Proteins were
transferred onto nitrocellulose ¢lters and blots were hybridized with
the rabbit anti-krox24 Ab (sc-110, Santa Cruz, CA, USA) or the
rabbit anti-c-fos Ab (sc-52, Santa Cruz) at a concentration of 0.25
Wg/ml. Immunocomplexes were revealed by a peroxidase-labeled anti-
rabbit IgG conjugate associated with the enhanced chemiluminescence
detection system (Amersham, Les Ulis, France).
3. Results and discussion
3.1. NT1-R-mediated activation of krox24
We have previously described that stimulation with NT of
CHO cells stably transfected with hNT1-R led to the induc-
tion of endogenous krox24 protein [14]. In order to examine
the transcriptional activation of krox24 gene we have also
generated a stable double transfected CHO cell line expressing
hNT1-R and a luciferase reporter linked to the 3395/+65
sequence of the murine krox24 promoter [14]. The speci¢c
involvement of NT1-R in both endogenous krox24 response
and reporter induction by NT was demonstrated by the pre-
venting e¡ect of the non-peptide antagonist SR 48692 in cells
expressing hNT1-R, whereas no modulation by the ligands
were observed in wild-type cells [14,16]. Regulatory elements
located within the 400 bp proximal krox24 upstream sequence
are mainly composed of four serum responsive elements
(SREs) and one cAMP response element (CRE) ([17] and
Fig. 1A). We ¢rst investigated those preferentially activated
following stimulation of NT1-R. Co-transfecting CHO cells
with NT1-R (p1274) and pUT112-krox24 (comprising the
3395/+65 sequence) resulted in an increase in reporter activity
of about 30-fold when stimulating with 30 nM NT, whereas
co-transfecting cells with pUT112-krox24 and the control
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Fig. 2. krox24 promoter analysis. A, B: CHO Wt cells were co-
transfected as described in the legend to Fig. 1, and treated with in-
creasing concentrations of NT for 90 min. The level of induction by
NT is de¢ned as the ratio of mean luciferase activities in stimulated
vs. unstimulated cells and is expressed as fold increase above basal
level.
Fig. 3. E¡ect of SR 48692 and SR 142948 on c-fos gene induction
by NT. A: Dose-response e¡ect of NT on the expression of c-fos-lu-
ciferase. CHO Wt cells were co-transfected with 10 Wg pAdNeoFos-
Luc and either 5 Wg hNT1-R (p1274) or the empty vector (p658).
Cells treated as described in the legend to Fig. 1 were stimulated
for 90 min with increasing concentrations of NT and mean lucifer-
ase activities in cell extracts from triplicate samples were deter-
mined. B: E¡ects of NT1-R antagonists on c-fos gene induction.
Cells treated as described in the legend to Fig. 1 were preincubated
for 5 min with increasing concentrations of the antagonists SR
48692 or SR 142948 prior to the addition of 1038 M NT. Results
are expressed as a percentage of luciferase values in cells pretreated
with the vehicle only before the addition of NT.
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plasmid empty of hNT1-R cDNA (p658) showed no modu-
lation of the reporter, con¢rming that NT e¡ects are mediated
by NT1-R (Fig. 1B). Deleting the sequence 3274/345 of the
krox24 promoter, comprising the two proximal SREs and the
CRE sequence led to a dramatic decrease of reporter induci-
bility (six-fold activation with 30 nM NT, 80% decrease, Fig.
2A). The deletion 3335/345 further contributed to reduce
activation from six-fold to two-fold. In addition, the deletion
3274/345 did not signi¢cantly a¡ect basal reporter activity
whereas the deletion 3335/345 led to a dramatic decrease
(more than 60%) of basal luciferase (Fig. 1B). Our results
indicate that elements comprised in the proximal 3275/345
sequence are necessary for maximal activation by NT. Similar
results were described for nerve growth factor (NGF) re-
sponse in PC12 cells and the authors demonstrated that mu-
tating either SRE1 or SRE2 reduced krox24 gene inducibility
by NGF [18]. Further deleting the sequence 3274/3335
nearly completely abolished the NT e¡ect (Fig. 2A). To ana-
lyze the potential involvement of the Ets binding sequence
located in this region (around 3315), we next investigated
whether introducing point mutations in the adjacent SRE3
altered reporter inducibility NT. Results of co-transfections
of hNT1-R with either the wild-type 3395/+65 krox24 se-
quence or the mutated version of SRE3 (krox24 mSRE3) in-
dicated that neither basal expression (Fig. 1C) nor the level of
induction by NT (Fig. 2B) was signi¢cantly modi¢ed by the
mutations, suggesting that there is no cooperative e¡ect be-
tween SRE3 and the adjacent Ets sequence for maximal tran-
scriptional activity.
3.2. NT1-mediated activation of c-fos and Elk-1
Since the c-fos promoter contains similar regulatory ele-
ments as the krox24 promoter [19], we next investigated
whether the c-fos gene could be activated by hNT1-R. In a
transient transfection assay of CHO cells with hNT1-R and
pAdFosLuc, a plasmid comprising the c-fos regulatory se-
quences linked to luciferase, we observed a dose-dependent
increase in luciferase activity following stimulation with NT
(Fig. 3A). The speci¢c involvement of hNT1-R in this activa-
tion was demonstrated by the absence of stimulation by NT in
co-transfection experiments with pAdFosLuc and the control
vector lacking NT1-R (Fig. 3A) and by the observation that
the antagonists SR 48692 and SR 142948 dose-dependently
prevented NT response in NT1-R-transfected cells (Fig. 3B).
We next asked whether the endogenous c-fos protein was
similarly regulated by NT receptor ligands in CHO cells stably
expressing hNT1-R, and we compared c-fos and krox24 in-
duction. Western blot analysis show that NT strongly induced
the amount of both proteins in CHO-hNT1-R cells (Fig. 4),
whereas NT has no e¡ect in CHO Wt cells (data not shown).
Maximal induction was obtained with concentrations of NT
ranging from 1038 M to 1037 M and was similar for both
proteins, which is consistent with reporter assays. The antag-
onists SR 48692 and SR 142948 alone had no e¡ect on basal
expression of either c-fos or krox24 in CHO-hNT1-R cells
(Fig. 4) or CHO Wt cells (data not shown). When CHO-
hNT1-R cells were treated with SR 48692 or SR 142948, a
dose-dependent inhibition of c-fos and krox24 expression
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Fig. 5. NT1-mediated activation of Elk-1. A: Dose-response e¡ect
of NT. CHO cells were co-transfected with 2.5 Wg hNT1-R
(p1274)+500 ng Gal4-Elk-1+7.5 Wg Gal4-Luc and treated as de-
scribed in the legend to Fig. 1. Mean luciferase activities in cell ex-
tracts from triplicate samples were determined following 5 h of stim-
ulation with NT. B: E¡ects of NT1-R antagonists. Cells transfected
as above were preincubated for 5 min with increasing concentrations
of SR 48692 or SR 142948 prior to the addition of 1038 M NT.
Results are expressed as a percentage of luciferase values in cells
pretreated with the vehicle only before the addition of NT.
Fig. 4. E¡ects of SR 48692 and SR 142948 on the expression of
krox24 and c-fos proteins by NT. CHO cells expressing hNT1-R
(CHO-hNT1-R) were treated for 90 min with NT, SR 48692, SR
142948, or pretreated for 5 min with the antagonists before the ad-
dition of NT. Protein extracts were prepared, run on SDS-PAGE,
and blotted onto nitrocellulose ¢lters as described in Section 2. Fil-
ters were hybrized with anti-c-fos or anti-krox24 Ab. Concentrations
of the ligands: 3 : untreated; +: 1038 M; ++: 1037 M; +++:
1036 M.
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mediated by NT was observed. Collectively, these results in-
dicate that SR 142948 and SR 48692 potently prevent krox24
and c-fos induction by NT, both at the protein level and at the
transcriptional level, demonstrating that the two early genes
are speci¢cally activated through NT1-R.
We have previously shown that NT stimulation of CHO
cells stably expressing NT1-R is followed by the transient
activation of MAPKs [14] and similar results were also re-
cently reported for NT2-R signalling in transfected CHO cells
[7]. The coordinate biological response mediated by the vari-
ous MAPK pathways was shown to converge at the SRE of
either c-fos [20^22] or krox24 [23] through ternary complex
factors (TCFs) including Elk-1 and SAP-1a. We thus inves-
tigated whether Elk-1 could be involved in the activation of
the early genes by NT1-R through the MAPK pathway. The
activity of TCFs, which are ubiquitously expressed in the cell,
is regulated by phosphorylation on serine/threonine residues
on the COOH terminal end. Using a transactivation reporter
assay for Elk-1, we observed a dose-dependent increase in
luciferase activity following stimulation with NT in CHO cells
co-transfected with NT1-R (Fig. 5A) but not in cells co-trans-
fected with the empty vector p658 (data not shown). In addi-
tion, treatment with the antagonists SR 48692 or SR 142948
prevented the NT-induced response in NT1-R expressing cells
(Fig. 5B). The antagonist potentials of both SR compounds in
the Elk-1 transactivation assay are in agreement with previous
ones in krox24 or c-fos reporter assays.
3.3. Role of cAMP regulatory elements in NT-mediated
transcriptional activation of krox24 and c-fos genes
In NT1-R-transfected CHO cells, it is well documented that
NT raises cAMP levels [24,25], an e¡ect which is prevented by
the antagonist SR 48692 [26]. Since both krox24 and c-fos
promoters contain a CRE element, and since we demonstrated
above that the region 3274/345 of the krox24 promoter, in-
cluding the CRE, was mainly involved in NT-mediated acti-
vation, we next asked whether cAMP could directly modulate
the expression of the early genes. The cAMP-inducing agent
forskolin, at a concentration of 1 WM, only slightly stimulated
luciferase activity from either krox24 (three-fold) or c-fos (1.3-
fold) reporter plasmids, as compared to the stimulation ob-
tained with NT (Table 1). Increasing the forskolin concentra-
tion to 1035 M did not further enhance luciferase activities
(data not shown). Furthermore, the e¡ect of forskolin was
additive with that of NT. Thus our results indicate that if
cAMP potentially contributes to transcriptional activation of
krox24 or c-fos by NT through the CRE, it is not su⁄cient to
drive optimal gene induction.
3.4. Krox24 and c-fos genes are induced through alternative
signalling pathways
We have previously shown that the NT1-R-mediated acti-
vation of MAPK was partially prevented by PTX, which ADP
ribosylates G proteins of the Go/Gi type [14]. As shown in
Table 1, pretreatment for 18 h with 10 ng/ml PTX also par-
tially prevented the induction by NT of krox24 (80%) and
Elk-1 (74%) but not c-fos. This result clearly indicates that
Elk-1-mediated gene activation may be restricted to krox24.
The coupling of NT1-R to Gq proteins, leading to phospho-
lipase C activation and subsequent inositol phosphate increase
and Ca2 mobilization, is well documented [26]. The direct
involvement of Gq in c-fos activation through the increase
in Ca2 is a possible explanation since the CRE binding ele-
ment is phosphorylated either by the cAMP-dependent pro-
tein kinase or the Ca2/calmodulin-dependent kinase at the
same site, serine-133 [27]. It has been also demonstrated
that members of the Rho family GTPases can link GK12 to
the transcriptional activation of the c-fos SRE, by a pathway
that is independent of TCF [28,29].
NT-mediated activation of MAPK and induction of krox24
protein expression also partially involve protein kinase C [14].
Using the protein kinase C inhibitor GF109203X we observed
that it equally but partially prevented the induction by NT of
reporter for krox24 (64%), Elk-1 (58%) and c-fos (51%) (Table
1). Thus, although the signalling pathways leading to activa-
tion of the three proteins may di¡er from the type of G pro-
tein coupling, they share common elements, including a pro-
tein kinase C.
4. Concluding remarks
In this paper, we have explored in detail the signalling
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Table 1
NT1-R-mediated activation of krox24, c-fos and Elk-1
Stimuli Luciferase activity (fold increase þ S.E.M.)
krox24 reporter c-fos reporter Elk-1 reporter
Untreated 1.00 þ 0.16 1.00 þ 0.49 ^
NT 8.53 þ 0.53 5.38 þ 0.65 ^
Forskolin 2.98 þ 0.35 1.33 þ 0.5 ^
Forskolin+NT 10.1 þ 0.8 7.32 þ 1.2 ^
Untreated 1.00 þ 0.06 1.00 þ 0.14 1.00 þ 0.52
NT 20.4 þ 1.24 38.74 þ 5.84 27.11 þ 4.44
PTX 0.96 þ 0.13 1.00 þ 0.12 0.89 þ 0.59
PTX+NT 4.06 þ 0.36 49.57 þ 5.36 6.33 þ 3.81
Untreated 1.00 þ 0.08 1.00 þ 0.13 1.00 þ 0.58
NT 19.01 þ 2.73 28.88 þ 1.37 33.16 þ 7.23
GFX 0.66 þ 0.11 0.59 þ 0.14 0.38 þ 0.27
GFX+NT 6.96 þ 1.23 8.67 þ 0.54 5.39 þ 1.97
CHO cells co-transfected with NT1-R and the indicated reporter construct were treated for 5 min with forskolin (1 WM) before the addition of NT
(1038 M), or for 18 h with PTX (10 ng/ml), or for 3 h with GF109203X (GFX, 1 WM) before the addition of NT (1037 M). Cells were further
stimulated for 1.5 h for the krox24 and c-fos reporters and for 5 h for the Elk-1 reporter. As a control, for each type of stimulation, cells were
pretreated with the vehicle. Results are expressed as fold increase in luciferase level above the level in untreated cells þ S.E.M.
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components associated with activation of NT1-R in trans-
fected CHO cells, and leading to the modulation of the early
genes krox24 and c-fos. We conclude that the transduction
pathways are not related to cAMP metabolism, and we pro-
vide new evidence for the cascade Gi/Go-coupled NT1 recep-
tor/p42/p44 MAPKs/Elk-1/krox24, whereas signalling to c-fos
does not involve coupling to Gi/Go proteins. Since stimulation
of both NT1-R and NT2-R is followed by the transient acti-
vation of MAPKs, and since NT and SR compounds exhibit
opposite pharmacological e¡ects (agonist or antagonist) on
the two types of receptor, it may be of particular interest to
investigate their functions in cells naturally co-expressing both
receptors.
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